World News: 15:30 GMT Thursday 6th December 2018. [Novartis International AG via Thomson Reuters ONE via SPi World News]
Novartis International AG Novartis investigational BYL719 alpelisib plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses Processed and transmitted by West Corporation
Thomson Reuters: 15:30 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.